Please login to the form below

Not currently logged in
Email:
Password:

Cell Therapeutics

This page shows the latest Cell Therapeutics news and features for those working in and with pharma, biotech and healthcare.

Rubius Therapeutics poaches Novartis’ Spencer Fisk

Rubius Therapeutics poaches Novartis’ Spencer Fisk

Novartis’former vice president and global head of cell and gene technical development and manufacturing Spencer Fisk has decided to join Rubius Therapeutics. ... Fish said: “Rubius is developing an entirely new class of ready-to-use cell therapeutics

Latest news

  • Celgene steps back from $1bn Sutro acquisition Celgene steps back from $1bn Sutro acquisition

    Now Celgene has decided to focus its involvement on four programmes headed to clinical trials - including an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA). ... Our goal is to continue to build momentum for promising antibody

  • Argos hit as kidney cancer immunotherapy fails phase III trial Argos hit as kidney cancer immunotherapy fails phase III trial

    Argos hit as kidney cancer immunotherapy fails phase III trial. Study discontinued as data shows renal cell carcinoma vaccine unlikely to meet targets. ... Argos Therapeutics' hopes of bringing lead cancer immunotherapy rocapuldencel-T to market anytime

  • Bayer helps bankroll new stem cell company BlueRock Bayer helps bankroll new stem cell company BlueRock

    Bayer helps bankroll new stem cell company BlueRock. Start-up receives $225m to develop cardiovascular and neurodegenerative disease therapies. ... There is a new player on the stem cell therapy stage, thanks to $225m in start-up funding from Bayer and

  • Novartis plans filing for lead CAR-T therapy early next year Novartis plans filing for lead CAR-T therapy early next year

    Novartis plans filing for lead CAR-T therapy early next year. Shows complete remission for 82 percent of paediatric and young adult B-cell ALL patients. ... The trial in B-cell ALL resumed with a protocol change, but was halted again two weeks ago after

  • Astellas adds to regenerative medicine unit with Ocata buy Astellas adds to regenerative medicine unit with Ocata buy

    Astellas adds to regenerative medicine unit with Ocata buy. Willpay around $379m for the cell therapy specialist. ... Astellas has agreed to buy cell therapy specialist Ocata Therapeutics for around $379m, boosting a regenerative medicine unit it set up

More from news
Approximately 9 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex, goserelin acetate implant for prostate, breast cancer, benign gynaecological disorders (marketed). ... Licence. 320. Lonza/ Sanofi. Large scale mammalian cell manufacturing facility for antibody

  • Deal Watch November 2016 Deal Watch November 2016

    One piece of unwelcome news this month was from Juno Therapeutics, which announced it had halted a phase 2 trial of JCAR015, its CAR T cell immunotherapeutic, in patients with relapsed ... This is despite some positive news for Juno released at the

  • Deal Watch February 2016 Deal Watch February 2016

    licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies. ... acquisition - product. 190. Annapurna

  • Pharma deals in August 2015 Pharma deals in August 2015

    Recent deals: acquired Chatham Therapeutics [$70m]; collaboration Coherus Biosciences, divested vaccines to Pfizer [$625m], global licence Cell Therapeutics for pacritinib. ... Acquisition of Priority Review Voucher. 350. Evotec. Sanofi. Beta cell

  • Pharma deals in June 2015 Pharma deals in June 2015

    Acquisition - business. 1, 153. Juno Therapeutics/ Celgene Corporation. 10-yr immunotherapy collaboration - CAR-T and T Cell Receptor (TCR) technologies; incl Juno's CD19 and CD22 directed CAR-T candidates. ... NewCo formation, collaboration. 760. Unum

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial

  • Oncology drugs under AMNOG

    Pixuvri: Polycomparator segmentation by the G-BA removes statistical power. Cell Therapeutics gained European approval for Pixuvri (pixantrone) in non-Hodgkin’ s B-cell lymphoma, on the basis of a trial

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics